Merck KGaA Surges as Upgraded Guidance Ignites AI Hopes

Merck KGaA is experiencing a significant surge in its stock price due to upgraded profit guidance for 2026 and strong demand for AI-linked semiconductor materials. The company's shares are also benefiting from revenue growth at Bio-Techne, a key takeover target expected to enhance Merck's Life Science arm.

This move is validating the company's shift towards rare diseases and higher-growth electronics. Investors are responding positively to these developments, which are helping the stock press against technical resistance.

Separately, Definium Therapeutics (DFTX) is experiencing volatility due to its reliance on upcoming trial results and regulatory decisions. The company has no commercial revenue and is burning cash quickly, leaving investors exposed to ongoing funding needs and potential setbacks in clinical trials or approval processes.